Superior Planning, LLC’s Zenas BioPharma ZBIO Stock Holding History

Superior Planning, LLC’s Portfolio ZBIO Stock Details ZBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.21K	Buy	+45	New	+$1.39K	﹤0.01%	1711

Other funds holding ZBIO

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return

Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

Silverarc Capital Management Boston, Massachusetts $854M AUM 179.73% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Superior Planning, LLC's ZBIO Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in Zenas BioPharma (ZBIO) in Q3 2026: 45 shares worth $1.21K. The stake represents ﹤0.01% of the portfolio and ranks #1711 among its holdings.

75 funds tracked by Wall St. Rank hold ZBIO as of Q3 2026.

Superior Planning, LLC held 45 shares of Zenas BioPharma worth $1.21K as of Q3 2026.
Zenas BioPharma was a new Superior Planning, LLC position in Q3 2026.
Zenas BioPharma made up ﹤0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #1711 holding.
75 funds tracked by Wall St. Rank held Zenas BioPharma as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.